INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 48m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
Public company

ROIVRoivant Sciences Ltd.

CIK 0001635088

EDGAR filingsOpen in network
Disclosed transactions29
Buys / sells0 / 7
Max Insider Score35
Connections9with evidence

ROIV · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
14
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$7.32M
200.0K sh
Oct 28, 2026Oct 30, 2026
traded Oct 28, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Sukhatme MayukhDirector, President & CIO · Oct 20, 2026
  • ← Insider ofevidence
    Oren IlanDirector · Sep 18, 2026
  • ← Insider ofevidence
    Gold Daniel AllenDirector · Sep 18, 2026
9
OI
Oren IlanDirector
ROIVRoivant Sciences Ltd.
Grant or award
A
—
810 sh
Oct 23, 2026
Oct 27, 2026
traded Oct 23, 2026
+4d
SEC FORM 4

Evidence

9
EB
Epperly Melissa B,Director
ROIVRoivant Sciences Ltd.
Tax withholding
F$4,233
116 sh
Oct 23, 2026Oct 27, 2026
traded Oct 23, 2026
+4dSEC FORM 4

Evidence

9
EB
Epperly Melissa B,Director
ROIVRoivant Sciences Ltd.
Grant or award
A—
513 sh
Oct 23, 2026Oct 27, 2026
traded Oct 23, 2026
+4dSEC FORM 4

Evidence

7
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$501K
14.1K sh
Oct 20, 2026Oct 22, 2026
traded Oct 20, 2026
+2dSEC FORM 4

Evidence

14
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$6.52M
185.9K sh
Oct 20, 2026Oct 22, 2026
traded Oct 20, 2026
+2dSEC FORM 4

Evidence

14
GM
Gline MatthewDirector, CEO
ROIVRoivant Sciences Ltd.
Tax withholding
F$1.16M
34.6K sh
Oct 16, 2026Oct 20, 2026
traded Oct 16, 2026
+4dSEC FORM 4

Evidence

15
SM
Sukhatme MayukhDirector, President & CIO
ROIVRoivant Sciences Ltd.
Tax withholding
F$670K
20.0K sh
Oct 16, 2026Oct 20, 2026
traded Oct 16, 2026
+4dSEC FORM 4

Evidence

12
PR
Pulik RichardCFO
ROIVRoivant Sciences Ltd.
Tax withholding
F$85K
2,129 sh
Sep 20, 2026Sep 22, 2026
traded Sep 20, 2026
+2dSEC FORM 4

Evidence

9
EB
Epperly Melissa B,Director
ROIVRoivant Sciences Ltd.
Grant or award
A—
10.5K sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

21
EB
Epperly Melissa B,Director
ROIVRoivant Sciences Ltd.
Grant or award
A—
5,054 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

9
GA
Gold Daniel AllenDirector
ROIVRoivant Sciences Ltd.
Grant or award
A—
5,054 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

9
GA
Gold Daniel AllenDirector
ROIVRoivant Sciences Ltd.
Grant or award
A—
10.5K sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

9
OI
Oren IlanDirector
ROIVRoivant Sciences Ltd.
Grant or award
A—
5,054 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

9
OI
Oren IlanDirector
ROIVRoivant Sciences Ltd.
Grant or award
A—
10.5K sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

16
EB
Epperly Melissa B,Director
ROIVRoivant Sciences Ltd.
Tax withholding
F$89K
2,179 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

0
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M—
200.0K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

10
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$1.55M
46.2K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

14
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$5.08M
153.8K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

5
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M$770K
200.0K sh
Jun 24, 2026Jun 26, 2026
traded Jun 24, 2026
+2dSEC FORM 4

Evidence

17
PR
Pulik RichardCFO
ROIVRoivant Sciences Ltd.
Grant or award
A—
60.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M$770K
200.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

23
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Open-market sale · 10b5-1 plan
SELL$5.92M
200.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

0
VE
Venker EricPresident & Immunovant CEO
ROIVRoivant Sciences Ltd.
Option exercise · 10b5-1 plan
M—
200.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
PR
Pulik RichardCFO
ROIVRoivant Sciences Ltd.
Grant or award
A—
84.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

17
HJ
Humes JenniferChief Accounting Officer
ROIVRoivant Sciences Ltd.
Grant or award
A—
29.2K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
HJ
Humes JenniferChief Accounting Officer
ROIVRoivant Sciences Ltd.
Grant or award
A—
27.2K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

9
EB
Epperly Melissa B,Director
ROIVRoivant Sciences Ltd.
Grant or award
A—
670 sh
Apr 17, 2026Apr 21, 2026
traded Apr 17, 2026
+4dSEC FORM 4

Evidence

35
GM
Gline MatthewDirector, CEO
ROIVRoivant Sciences Ltd.
Open-market sale
SELL$8.45M
289.8K sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

← Insider ofevidence
Humes Jennifer
Chief Accounting Officer · Apr 22, 2026
  • ← Insider ofevidence
    Venker EricPresident & Immunovant CEO · Apr 22, 2026
  • ← Insider ofevidence
    Pulik RichardCFO · Apr 22, 2026
  • ← Insider ofevidence
    Epperly Melissa B,Director · Apr 21, 2026
  • ← Insider ofevidence
    Gline MatthewDirector, CEO · Apr 20, 2026